Letter to Shareholders from the Company's CEO, Rik J Deitsch.
Dear Fellow Shareholders of Nutra Pharma: As we are getting close to the end of the year, I wanted to take this opportunity to update you on the current status of the Company, provide a review of 2016 and briefly outline our goals and expectations for the coming months. Nutra Pharma Corporation operates as a biotechnology and biopharmaceutical company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the manageme
Nutra Pharma Letter to Shareholders
December 27, 2016 Nutra Pharma CEO, Rik J Deitsch, has published a letter to Shareholders outlining the current efforts and the future goals of the Company. December 27, 2016 -- Coral Springs, Florida -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company marketing Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, and which is also developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneur